Cytovation builds on over 15 years of cutting-edge research from two leading Norwegian institutions; University of Bergen and Haukeland University Hospital. Led by a highly experienced management team and world-renowned experts in tumour biology, an extensive research program has focused on engineering synthetic peptides with unique properties. CyPep-1, the company’s lead candidate, is being developed as a first-in-class lytic agent for the treatment of solid tumors.
Associate professor of medicine with more than 15 years experience in cancer research.
Serial entrepreneur with over 25 years of experience as managing director in global industrial enterprises.
20+ yrs of senior general management experience in specialty pharma (immunology & dermatology).
25+ years experience in the pharma sector. Senior management roles in Pfizer and Baxter.
25+ years of experience in phase I-IV trials in the clinical research industry in various positions, with recent years in oncology research.
Professor Emeritus and University of Bergen. International KOL Cervical Cancer. Principal investigator HPV vaccines.
Founder and CEO Drug Development & Regulation (DDR). Former Head of Safety and Efficacy of Medicines, European Medicines Agency.
Professor of Oncology University of Bergen. Over 35 years of research experience with 300+ Publications.
Professor of Cancer Biology University of Bergen. Director of Oncology in Luxembourg.
Medical doctor with 15 years of senior executive management experience.
Experienced in finance and executive management. Executive board member Central bank of Norway. Previously CEO at Vesta, Nordea and Holberg.
